Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (27410)	1/14/1999 12:24:00 PM
From: Sleepman	Respond to of 32384

Henry: While I am a big believer in Ligand, I am wondering about Robinson's predictions on sales of both Ontak and Panretin Gel. I really do not know how he is coming up with numbers like 35 million for Panretin and 50 Mil for Ontak. If you could give an analysis of this, I would be much appreciative. Also, could you go into the details of the Lilly deal. As I recall, they have the rights to Targretin for diabetes indications only. I was concerned about that, as the cancer indications will bring alot higher costs per treatment to the company (ie more money). If they do not procede with Targretin for diabetes, Will Ligand see all the revenue for the cancer indications? Thanks, Dan